Belantamab mafodotin

Antibody–drug conjugate

Also known as GSK2857916

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
CN
  • With bortezomib and dexamethasone (BVd) for relapsed or refractory multiple myeloma after at least one prior line
Product first approved 20261stoncology.com
EU
  • Adults with relapsed or refractory multiple myeloma: with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone
Product first approved 2025EMA
JP
  • Relapsed or refractory multiple myeloma: Blenrep with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone
Product first approved 2025cancernetwork.com
UK
  • Adults with relapsed or refractory multiple myeloma: with bortezomib plus dexamethasone, or with pomalidomide plus dexamethasone
Product first approved 2025biopharminternational.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Multiple Myeloma
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT06956170 · GlaxoSmithKline
2022-02-10 – 2029-06-25 · Multiple Myeloma
What this study did
NCT04549363 · GlaxoSmithKline
2020-12-21 – 2022-11-21 · Multiple Myeloma
What this study did
Phase 2 (20)
Multiple Myeloma
NCT05847569 · Mayo Clinic
2024-01-04 – 2034-06-29 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07748689 · Polish Myeloma Consortium
2026-10 – 2033-03 · Relapsed / Refractory Multiple Myeloma
What this study did
NCT07614360 · GlaxoSmithKline
2026-08-03 – 2031-02-11 · Multiple Myeloma
What this study did
NCT05922501 · Massachusetts General Hospital
2024-05-31 – 2030-12-31 · Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
What this study did
NCT04680468 · University of Pennsylvania
2021-06-02 – 2028-11-01 · Myeloma
What this study did
NCT05874193 · Cristiana Costa Chase, DO
2026-11 – 2028-11 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05208307 · Emory University
2022-07-21 – 2028-10-21 · Plasma Cell Myeloma
What this study did
NCT05789303 · University of Chicago
2023-05-30 – 2028-07-01 · Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT04876248 · Roswell Park Cancer Institute
2024-08-19 – 2027-07-29 · Plasma Cell Myeloma
What this study did
NCT04802356 · PETHEMA Foundation
2021-04-07 – 2026-06 · Multiple Myeloma
What this study did
NCT05064358 · GlaxoSmithKline
2022-03-03 – 2026-02-10 · Multiple Myeloma
What this study did
NCT05117008 · Medical College of Wisconsin
2022-07-19 – 2024-01-15 · Refractory Multiple Myeloma, Relapse Multiple Myeloma
What this study did
Other / comorbidity
NCT07844200 · Medical Association for the Study of Cancer Biology and Treatment
2027-02 – 2031-12 · SLE - Systemic Lupus Erythematosus
What this study did
NCT04617925 · Stichting European Myeloma Network
2021-02-26 – 2025-07-17 · AL Amyloidosis
What this study did
NCT04676360 · Jacob Soumerai, MD
2021-07-01 – 2024-11-26 · Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
What this study did
Phase 1/2 (28)
Multiple Myeloma
NCT04822337 · Wake Forest University Health Sciences
2021-05-19 – 2032-11 · Multiple Myeloma
What this study did
NCT07612787 · Centre Hospitalier Universitaire de Saint Etienne
2026-12-01 – 2031-01-01 · Myeloma Multiple
What this study did
NCT06232044 · Alliance for Clinical Trials in Oncology
2025-04-23 – 2030-08-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05853965 · Universitätsklinikum Hamburg-Eppendorf
2023-06-28 – 2028-12 · Multiple Myeloma, Multiple Myeloma in Relapse
What this study did
NCT04808037 · Hellenic Society of Hematology
2021-02-22 – 2028-11-08 · Multiple Myeloma
What this study did
NCT05714839 · GlaxoSmithKline
2023-06-14 – 2028-08-03 · Multiple Myeloma
What this study did
NCT05060627 · PETHEMA Foundation
2021-12-20 – 2028-05-30 · Relapsed Multiple Myeloma
What this study did
NCT04643002 · Sanofi
2021-01-25 – 2028-04-20 · Plasma Cell Myeloma Refractory
What this study did
NCT03715478 · Canadian Myeloma Research Group
2018-11-26 – 2027-12-31 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07084896 · GlaxoSmithKline
2020-06-08 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07150091 · GlaxoSmithKline
2022-07-19 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07150104 · GlaxoSmithKline
2022-08-31 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07217119 · GlaxoSmithKline
2019-11-26 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07217184 · GlaxoSmithKline
2021-07-29 – 2027-03-11 · Multiple Myeloma
What this study did
NCT05002816 · Yale University
2022-02-21 – 2026-12 · Multiple Myeloma
What this study did
NCT05581875 · Hellenic Society of Hematology
2022-10-20 – 2026-10-31 · Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
What this study did
NCT05573802 · Hellenic Society of Hematology
2023-07-14 – 2026-10-31 · Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05280275 · Hellenic Society of Hematology
2022-04-13 – 2026-03-15 · Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05493618 · Hackensack Meridian Health
2022-12 – 2025-11 · Multiple Myeloma, Refractory
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT04896658 · University of Maryland, Baltimore
2021-12-03 – 2024-12-01 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT06655818 · GlaxoSmithKline
2021-03-09 – 2024-02-14 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT06160609 · GlaxoSmithKline
2019-10-07 – 2023-01-09 · Relapsed/Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT05145816 · University of Texas Southwestern Medical Center
2024-02-15 – 2027-09-01 · AL Amyloidosis, Amyloidosis
What this study did
Phase 1 (15)
Multiple Myeloma
NCT07831122 · Canadian Myeloma Research Group
2026-12 – 2033-03 · Relapsed Refractory Multiple Myeloma (RRMM)
What this study did
NCT07720843 · Montefiore Medical Center
2026-09-01 – 2032-03 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07609706 · GlaxoSmithKline
2026-10-23 – 2031-08-22 · Multiple Myeloma
What this study did
NCT04091126 · GlaxoSmithKline
2019-12-18 – 2028-03-10 · Multiple Myeloma
What this study did
NCT05556798 · Memorial Sloan Kettering Cancer Center
2022-10-04 – 2027-10 · Multiple Myeloma
What this study did
NCT04398745 · GlaxoSmithKline
2020-10-09 – 2027-03-11 · Multiple Myeloma
What this study did
NCT05055063 · M.D. Anderson Cancer Center
2022-05-18 – 2027-02-02 · Myeloma
What this study did
NCT05065047 · M.D. Anderson Cancer Center
2023-01-05 – 2025-11-06 · Multiple Myeloma
What this study did
NCT04398680 · GlaxoSmithKline
2021-04-20 – 2025-11-04 · Multiple Myeloma
What this study did
NCT03828292 · GlaxoSmithKline
2019-03-14 – 2024-09-05 · Multiple Myeloma
What this study did
NCT04892264 · Mayo Clinic
2021-06-03 – 2024-03-18 · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02064387 · GlaxoSmithKline
2014-07-29 – 2019-08-01 · Multiple Myeloma
What this study did
Other / comorbidity
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Multiple Myeloma
NCT05461209 · Janssen Research & Development, LLC
2022-10-20 – 2024-10-31 · Relapsed/ Refractory Multiple Myeloma
What this study did

Competitive landscape

This mechanism is crowded: 33 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belantamab Mafodotin: this drugApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CT071Phase 1/2Cell therapyGPRC5Dnot yet gradedNo reviewed efficacy summary in this indication
EltanexorPhase 1/2—XPO1 (exportin-1)Weak signalNo reviewed efficacy summary in this indication
EzobresibPhase 1/2Small moleculeBETnot yet gradedNo reviewed efficacy summary in this indication
Galinpepimut-SPhase 1/2VaccineWT1 (Wilms Tumor-1 protein)not yet gradedNo reviewed efficacy summary in this indication
GIC-102Phase 1/2Cell therapyAllogeneic natural killer (NK) cell therapy (non-CAR)Weak signalNo reviewed efficacy summary in this indication
HuL001Phase 1/2Monoclonal antibodyENO1 (alpha-enolase 1)not yet gradedNo reviewed efficacy summary in this indication
ICP-490Phase 1/2Small moleculeCereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication
IDP-121Phase 1/2Small moleculec-Mycnot yet gradedNo reviewed efficacy summary in this indication
Pamlectabart TismanitinPhase 1/2Antibody–drug conjugateBCMAnot yet gradedNo reviewed efficacy summary in this indication
SENL103Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
Trovocabtagene Autoleucel (C-CAR088)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
Zevorcabtagene AutoleucelPhase 1/2Cell therapyBCMAWeak signal
NCT03975907: LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR).
NCT03915184: LUMMICAR STUDY 2 (NCT03915184): objective response rate 100% in evaluable relapsed/refractory multiple myeloma patients.
ALLO-715Phase 1Cell therapyBCMAWeak signal
NCT04093596: UNIVERSAL phase 1 trial (NCT04093596, allogeneic anti-BCMA CAR T ALLO-715 in R/R multiple myeloma): ORR 55.8% across all 43 dosed patients; in the 24 patients at the optimal (DL3) dose plus ALLO-647 lymphodepletion, ORR 70.8% (45.8% VGPR+, 25% CR/sCR), median duration of response 8.3 months.
BCMA CAR-NK (Hrain)Phase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BP2202Phase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CART-BCMAPhase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CBG002Phase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
FT576Phase 1Cell therapyBCMAWeak signalFeatured results are dose-finding only in this race
IM21 CAR-T CellsPhase 1Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
IMV102Phase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
KLN-1010Phase 1Gene therapy / editingBCMAnot yet gradedNo reviewed efficacy summary in this indication
P-BCMA-ALLO1Phase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
UF-KURE-BCMAPhase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
UWD-00BPhase 1Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA-CART (Bioray Laboratories)
—(overall)
Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BRL-305
—(overall)
Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
UTAA17
—(overall)
Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Bb21217DiscontinuedCell therapyBCMAWeak signal
NCT03274219: BMS/bluebird bio press release explicitly names the trial identifier NCT03274219 (CRB-402, bb21217 CAR-T in RRMM). This interim readout covers 38 of the trial's eventual 72 patients (this record's enrollment_count matches the trial's final total of 72). CRS in 66% of the 38-patient interim cohort (1 fatal Grade 5 event); at the 150x10^6 dose, ORR 83% (10/12) including 4 CR/sCR and 6 VGPR.
CB-011DiscontinuedCell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CYAD-211DiscontinuedCell therapyBCMAWeak signal
NCT04613557: IMMUNICY-1 (NCT04613557), final company update (21 Dec 2022): partial response in 5 of 17 evaluable patients.
PHE885DiscontinuedCell therapyBCMAWeak signal
NCT04318327: Part A, 55 patients with relapsed or refractory multiple myeloma given one infusion at one of four flat target doses (2.5 to 20 x 10^6 CAR T cells): overall response rate 98%, stringent complete response rate 55%; 35 of 44 evaluable patients (80%) reached minimal residual disease negativity (Sci Transl Med 2026).

Large race: only the 93 furthest-along competitors are listed; 74 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Belantamab mafodotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (10)
February 2027 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-02-02 · NCT05055063 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1/2AL Amyloidosis, AmyloidosisRecruiting
Est. primary completion 2027-03-01 · NCT05145816 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05853965 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06-01 · NCT03715478 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2027-08-05 · NCT07742527 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT05556798 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-10-21 · NCT05208307 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05091372 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT07612787 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-01 · NCT05789303 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-08-03 · NCT05714839 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-09-08 · NCT04808037 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT05922501 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-02-28 · NCT07614360 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-06-29 · NCT05847569 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 2SLE - Systemic Lupus ErythematosusNot yet recruiting
Est. primary completion 2030-02 · NCT07844200 · CT.gov ↗
What to watch
March 2030 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2030-03 · NCT07720843 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
2031 (3)
April 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07609706 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
2033 (3)
January 2033 (2)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2033-01 · NCT07831122 · CT.gov ↗
What to watch
Phase 2AmyloidosisRecruiting
Est. primary completion 2033-01-12 · NCT07224672 · CT.gov ↗
What to watch
March 2033 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2033-03 · NCT07748689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 April 2026ApprovalBlenrep approved in China for 2L+ relapsed/refractory multiple myeloma
CN, NMPA · Source ↗
23 October 2025ApprovalFDA approves Blenrep (BVd) for relapsed/refractory multiple myeloma
US, FDA · Source ↗